cyc 202 has been researched along with camptothecin in 13 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (camptothecin) | Trials (camptothecin) | Recent Studies (post-2010) (camptothecin) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 13,002 | 2,229 | 5,391 |
| Protein | Taxonomy | cyc 202 (IC50) | camptothecin (IC50) |
|---|---|---|---|
| Histone deacetylase 3 | Homo sapiens (human) | 0.05 | |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | 7.4 | |
| DNA topoisomerase 1 | Homo sapiens (human) | 1.9799 | |
| Somatostatin receptor type 1 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 2 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 4 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 3 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 5 | Homo sapiens (human) | 0.0022 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.97 | |
| Histone deacetylase 4 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 7 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 2 | Homo sapiens (human) | 0.05 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 11 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 8 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 9 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 5 | Homo sapiens (human) | 0.05 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR | 1 |
| Kabir, M; Kerns, E; Nguyen, K; Shah, P; Sun, H; Wang, Y; Xu, X; Yu, KR | 1 |
| Kabir, M; Kerns, E; Neyra, J; Nguyen, K; Nguyễn, ÐT; Shah, P; Siramshetty, VB; Southall, N; Williams, J; Xu, X; Yu, KR | 1 |
| Doniger, J; Mayner, R; Sadaie, MR | 1 |
| Abal, M; Bras-Goncalves, R; De Cremoux, P; Fsihi, H; Judde, JG; Louvard, D; Magdelenat, H; Poupon, MF; Robine, S | 1 |
| Jope, RS; Song, L | 1 |
| Abolmaali, ND; Tokalov, SV | 1 |
| Auladell, C; Beas-Zarate, C; Camins, A; Folch, J; Junyent, F; Pallàs, M; Pizarro, JG; Verdaguer, E | 1 |
| Ardelt, MA; Brandl, L; De Toni, EN; Ehrlich, SM; Gerbes, AL; Kirchner, T; Lehr, T; Liebl, J; Mayr, D; Vollmar, AM; Zahler, S | 1 |
1 review(s) available for cyc 202 and camptothecin
| Article | Year |
|---|---|
A novel approach to develop anti-HIV drugs: adapting non-nucleoside anticancer chemotherapeutics.
Topics: Anti-HIV Agents; Antimetabolites; Antineoplastic Agents; Apoptosis; Camptothecin; Cyclin-Dependent Kinases; Flavonoids; HIV; HIV Infections; Humans; Piperidines; Purines; Receptors, Estrogen; Roscovitine; Topoisomerase I Inhibitors; Virus Replication | 2004 |
12 other study(ies) available for cyc 202 and camptothecin
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Highly predictive and interpretable models for PAMPA permeability.
Topics: Artificial Intelligence; Caco-2 Cells; Cell Membrane Permeability; Humans; Models, Biological; Organic Chemicals; Regression Analysis; Support Vector Machine | 2017 |
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
Topics: Drug Discovery; Organic Chemicals; Pharmaceutical Preparations; Solubility | 2019 |
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
Topics: Animals; Computer Simulation; Databases, Factual; Drug Discovery; High-Throughput Screening Assays; Liver; Machine Learning; Male; Microsomes, Liver; National Center for Advancing Translational Sciences (U.S.); Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Rats; Rats, Sprague-Dawley; Retrospective Studies; United States | 2020 |
Enhanced sensitivity to irinotecan by Cdk1 inhibition in the p53-deficient HT29 human colon cancer cell line.
Topics: Camptothecin; CDC2 Protein Kinase; Cell Cycle; Cyclin B; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Enzyme Activation; Enzyme Inhibitors; HT29 Cells; Humans; Irinotecan; Mutation; Purines; Roscovitine; Tumor Suppressor Protein p53 | 2004 |
Cellular stress increases RGS2 mRNA and decreases RGS4 mRNA levels in SH-SY5Y cells.
Topics: Camptothecin; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase 2; Humans; Neuroblastoma; Purines; RGS Proteins; RNA, Messenger; Roscovitine; Topoisomerase I Inhibitors | 2006 |
Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Line, Tumor; Drug Screening Assays, Antitumor; Flow Cytometry; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Lung Neoplasms; Models, Genetic; Mutation; Piperazines; Purines; Roscovitine; Tumor Suppressor Protein p53 | 2010 |
Antiapoptotic effects of roscovitine on camptothecin-induced DNA damage in neuroblastoma cells.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Calpain; Camptothecin; Cell Cycle Proteins; Cell Line, Tumor; Cyclin-Dependent Kinase 5; Dipeptides; DNA Damage; DNA-Binding Proteins; Humans; Morpholines; Neuroblastoma; Protein Serine-Threonine Kinases; Purines; Pyrones; Roscovitine; Tumor Suppressor Proteins | 2011 |
Targeting cyclin dependent kinase 5 in hepatocellular carcinoma--A novel therapeutic approach.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Hepatocellular; Cyclin-Dependent Kinase 5; Cyclin-Dependent Kinases; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Liver Neoplasms; Mice; Mice, SCID; Purines; RNA, Neoplasm; Roscovitine; Treatment Outcome | 2015 |